[go: up one dir, main page]

WO2006040779A3 - Controlled release gastric floating matrix formulation containing imatinib - Google Patents

Controlled release gastric floating matrix formulation containing imatinib Download PDF

Info

Publication number
WO2006040779A3
WO2006040779A3 PCT/IN2005/000333 IN2005000333W WO2006040779A3 WO 2006040779 A3 WO2006040779 A3 WO 2006040779A3 IN 2005000333 W IN2005000333 W IN 2005000333W WO 2006040779 A3 WO2006040779 A3 WO 2006040779A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
formulation containing
gastric floating
matrix formulation
floating matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2005/000333
Other languages
French (fr)
Other versions
WO2006040779A2 (en
Inventor
Durga Maheswari Parvataneni
Appala Swamy Naidu Rongala
Khadgapathi Podile
Chowdary Nannapaneni Venkaiah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of WO2006040779A2 publication Critical patent/WO2006040779A2/en
Publication of WO2006040779A3 publication Critical patent/WO2006040779A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical formulation and its process for the preparation of controlled release gastric floating matrix solid oral dosage form of Imatinib or its pharmaceutically acceptable salts and its polymorphs such as β, α2, Form I and Form 2 thereof for once daily administration in the form of coated tablet or minitablets and / or pellets filled in hard gelatin capsules.
PCT/IN2005/000333 2004-10-11 2005-10-06 Controlled release gastric floating matrix formulation containing imatinib Ceased WO2006040779A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1049CH2004 2004-10-11
IN1049/CHE/2004 2004-10-11

Publications (2)

Publication Number Publication Date
WO2006040779A2 WO2006040779A2 (en) 2006-04-20
WO2006040779A3 true WO2006040779A3 (en) 2006-08-17

Family

ID=36148723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000333 Ceased WO2006040779A2 (en) 2004-10-11 2005-10-06 Controlled release gastric floating matrix formulation containing imatinib

Country Status (1)

Country Link
WO (1) WO2006040779A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2007106957A1 (en) * 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
JP2010521477A (en) * 2007-03-12 2010-06-24 ドクター レディズ ラボラトリーズ リミテッド Imatinib mesylate
FR2918566B1 (en) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa STABLE PHARMACEUTICAL COMPOSITION OF A WATER SOLUBLE SALT OF VINFLUNINE.
EP2086520A1 (en) * 2007-09-25 2009-08-12 Teva Pharmaceutical Industries Ltd. Imatinib compositions
EP2255792A1 (en) * 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
CZ2009570A3 (en) 2009-08-26 2011-03-09 Zentiva, K. S. Preparation, stabilization and use of imatinib mesylate polymorphs for development of medicinal forms
RU2013110058A (en) 2010-08-11 2014-09-20 Синтон Б.В. PHARMACEUTICAL GRANULATE CONTAINING IMATINIB MESILATE
WO2012080703A1 (en) * 2010-12-15 2012-06-21 Cipla Limited Pharmaceutical composition comprising imatinib
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
US20150110871A1 (en) * 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090750A1 (en) * 2002-04-24 2003-11-06 Board Of Regents, The University Of Texas System Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera
WO2003090720A1 (en) * 2002-04-23 2003-11-06 Novartis Ag High drug load tablet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090720A1 (en) * 2002-04-23 2003-11-06 Novartis Ag High drug load tablet
WO2003090750A1 (en) * 2002-04-24 2003-11-06 Board Of Regents, The University Of Texas System Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera

Also Published As

Publication number Publication date
WO2006040779A2 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
FI97686C (en) A method of making beads for the purpose of producing controlled release products
US10512621B2 (en) Methods of treating posttraumatic stress disorder with acamprosate salts
CN102065847A (en) Pharmaceutical formulation containing angiotensin-II receptor blocker
WO2006040779A3 (en) Controlled release gastric floating matrix formulation containing imatinib
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
BR0012981A (en) Hydrodynamically Balanced Oral Drug Release System
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
WO2006125819A3 (en) Oral microparticulate, anti-misuse drug formulation
CA2065652A1 (en) Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts
WO2007122635A3 (en) Controlled release formulation comprising anti-epileptic drugs
HUP0004966A3 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
NO20071044L (en) Dosage forms with enterally coated tablet cores
PT1411921E (en) Pharmaceutical compositions containing terbinafine and use thereof
WO2002024203A3 (en) Controlled release formulations for oral administration
WO2007086079A3 (en) Sustained release dosage form of phenothiazine derivatives containing channelizer
CN104379138B (en) Acamprosate formulations, methods of use thereof, and combinations comprising acamprosate formulations
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
CA2516327A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid
WO2006031420A3 (en) Multi-layer tablets and bioadhesive dosage forms
WO2007146068A3 (en) Controlled release alfuzosin hydrochloride formulation
WO2018206923A1 (en) Novel formulations
WO2004089333A3 (en) A stable benzimidazole formulation
WO2006117803A2 (en) Transmucosal drug delivery systems
US20070009599A1 (en) Asymmetrically coated table
WO2008059522A3 (en) Herbal gastrointenstinal controlled drug delivery dosage forms including pellets and process for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase